Engineering Immune Organoids to Study Pediatric Cancer
Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
Gustave Roussy, Cancer Campus, Grand Paris
108 participants
May 12, 2023
INTERVENTIONAL
Conditions
Summary
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Skin biopsy
Fresh tumor sample
Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
Healthy tissue from the tumor site whenever possible
Spinal cerebrospinal fluid (SCF) whenever possible
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05890781